10 Best Get Rich Quick Stocks to Buy Now

5. Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Upside potential as of July 8, 2025: 326.8%

Beta (5Y Monthly): 2.71

Analysts at Raymond James have reinitiated coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) with an Outperform rating and a price target of $11, implying an upside potential of nearly 326%. This optimism is derived from the company’s lead drug candidate, BDTX-1535, which has demonstrated promising results in patients already treated with osimertinib.

The research firm views this efficacy as an improved first-line treatment setting, mainly for patients with non-classical mutations, where ongoing treatments have limited effectiveness. What’s even interesting is that Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) targets a niche market through BDTX-1535 in contrast to large enterprises working to address a broad range of EGFR mutations. This means that the company is prioritizing selectivity over wild-type EGFR while offering greater activity against atypical mutations.

Additionally, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) exhibits robust financials, with a cash runway adequate till at least the last quarter of FY27, thus allowing the company to maintain flexibility to lead a first-line non-small cell lung cancer study in non-classical mutations upon FDA feedback.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), based in Massachusetts, is a clinical-stage oncology company that identifies and develops MasterKey therapies targeting patients with genetically defined tumors. Founded in 2014, the company is committed to making a significant impact on oncology through innovative science.